Phase II study of weekly topotecan with bevacizumab in platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancers

Trial Profile

Phase II study of weekly topotecan with bevacizumab in platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancers

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Topotecan (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top